Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073272 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| Cyclohexylglycyl SCHEMBL156537 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL7868412 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| Cyclohexylglycyl SCHEMBL122348 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL21977981 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL24316913 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL21969684 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL21981265 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL20819999 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 | |
| SCHEMBL3578175 | 1.00 | DPP4 (0.57) | DPP4EPHX1GRM2DPP7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | DPP4 817/4885EPHX1 1515/4885GRM2 850/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | DPP4 817/4885EPHX1 1515/4885GRM2 850/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | DPP4 817/4885EPHX1 1515/4885GRM2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.